2Strandberg TE, Kolehmainen L, Yuorio A. Evaluation andcal review [J]. J Med Assoc, 2014,312(11): 1136-44.
3Korneva VA, KyznetsovaTIu, MandeFshtamMIu, et al.The clinical manifestations of atherosclerosis in familialhypercholesterolemia [J]. Ter Arkh, 2014, 86 (1): 18-22.
4Gasevic D, Carlsson AC, Lesser IA, et al. The associationbetween “hypertriglyceridemic waist” and sub-clinical ath-erosclerosis in a multiethnic population: a cross-sectionalstudy [J]. Lipids Health Dis, 2014, 13: 38.
5Endo A. The discovery and development of HMG-CoAreductaseinhibitor[J]. J Lip Research, 1992, 33: 1569-73.
6Hye-Young Kang,Su-Kyoung Ko,Danny Liew.??Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: The Korean Individual-Microsimulation Model for Cardiovascular Health Interventions(J)Clinical Therapeutics . 2009 (12)
7Sang-Hak Lee,Kyoung-Im Cho,Jang-Young Kim,Young Keun Ahn,Seung-Woon Rha,Yong-Jin Kim,Yun-Seok Choi,Si Wan Choi,Dong Woon Jeon,Pil-Ki Min,Dong-Ju Choi,Sang Hong Baek,Kwon Sam Kim,Young Sup Byun,Yangsoo Jang.??Non-lipid effects of rosuvastatin–fenofibrate combination therapy in high-risk Asian patients with mixed hyperlipidemia(J)Atherosclerosis . 2012 (1)
8U. Kassner,A. Vogt,A. Rosada,F. Barz,E. Giannakidou-Jordan,H.K. Berthold,E. Steinhagen-Thiessen.??Designing a study to evaluate the effect of apheresis in patients with elevated lipoprotein(a)(J)Atherosclerosis (Supplements) (Component) . 2009 (5)
